SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

SAB Biotherapeutics

04/08/2026 15:21

SAB Biotherapeutics Inc SABS.OQ SABS.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026

​LSEG's mean analyst estimate for SAB Biotherapeutics Inc is for a loss of 29 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for SAB Biotherapeutics Inc is $12.00, about 216.6% above its last closing price of $3.79
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.24
-0.23
-0.35
Missed
-53.3
Dec. 31 2026
-0.19
-0.20
-0.35
Missed
-76.1
Sep. 30 2025
-0.43
-0.51
-0.15
Beat
70.4​
Jun. 30 2025
-0.82
-0.80
-1.09
Missed
-36.9
​​Mar. 31 2025
-1.07
-1.03
-0.56
Beat
45.6
Dec. 31 2024
-1.16
-1.23
Missed
-5.3​
Sep. 30 2024
-1.09
-1.09
-1.12
Missed
-2.8
Jun. 30 2024
-1.12
-1.13
-0.79
Beat
30.1
This summary was machine generated August 4 at 14:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)